This content is restricted.
Brief
"On November 29, 2024, the European Medicines Agency (EMA) issued an update regarding Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024. The PRAC concluded that currently available evidence does not support a link between doxycycline and suicidality risk, while new recommendations were agreed for Veoza to minimise the risk of liver injury through monitoring of liver function before and during treatment."
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested